Zhen Li^1,2, Xinya Yu¹, Boning Wu³, Jialin Zhang¹, Xinyu Ju¹, Yajun Wang¹, Jieli Song¹, Qiao Liu⁴, Peng Huang^4,5,*, Qi Ding^6,*, Yupeng Wu^1,7,8,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.084987 - 14 September 2026

Abstract Background: Fascin actin-bundling protein 1 (FSCN1) modulates the expression of key lipogenic enzymes fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD1) in colorectal cancer (CRC), but the underlying mechanisms remain elusive. Methods: Bioinformatics analyses were performed to evaluate FSCN1 expression and its prognostic value in CRC. Intracellular lipid levels following FSCN1 knockdown were assessed by Nile Red/DAPI co-staining and triglyceride quantification, and further validated by Oil Red O staining of xenograft tumors. Expression levels of key metabolic enzymes were measured by qRT-PCR and Western blotting. RNA sequencing identified FSCN1-associated pathways, which were functionally investigated using pharmacological inhibitors. Results: FSCN1… More > Graphic Abstract

Xiangui Liu^1,#, Jianhua Liu^2,#, Qingbin Meng^1,*, Yongsheng Shao¹

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.082954 - 14 September 2026

Abstract Objectives: There is debate over the effect of sevoflurane (SEV) on different cancers. This study aims to explore SEV’s role in colon cancer (CC) progression. Methods: The CC cell lines were treated with SEV at concentrations of 1.7%, 3.4%, and 5.1%. Cell proliferation, apoptosis, migration, and invasion were assessed using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) incorporation, colony formation assay, flow cytometry, Western blot, scratch assay, and Transwell assay. A xenograft tumor model was established to evaluate the effect of SEV in vivo. Expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2), p62 (sequestosome-1), microtubule-associated protein… More > Graphic Abstract

Li Li^1,#, Jianhua Wang^1,#, Feilong Zhou², Lingjun Geng^1,*, Kongwang Hu^1,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.080204 - 14 September 2026

Abstract Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with limited treatment options for advanced-stage patients. DNA polymerase theta (POLQ) is overexpressed in various cancers, but its role and underlying mechanisms in CRC remain not fully elucidated. This study aimed to investigate the expression, prognostic value, biological functions, and molecular mechanisms of POLQ in CRC. Methods: POLQ expression was analyzed using public databases and 55 paired clinical samples. Lentivirus-mediated knockdown and overexpression were employed to assess CRC cell proliferation, migration, and invasion. Single-cell transcriptomics and CellChat analysis were used to explore the tumor… More >

Daniel Thomas Jones^1,*, Tajveer Sangha¹, Arman Manjikian¹, Micheal Ghobrial¹, Qasim Shawesh¹, Emaan Tiwana¹, Emi Hearn¹, Arash Latif¹, Elaine Tupas¹, Aishwarya Hanspal¹, Rishi Kumar Nanda², Ramaditya Srinivasmurthy³, Jason Ta⁴, Meghana Pandit³, Charles Abraham Joseph Larson⁵, Kyaw Zin Thein⁶

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.078524 - 14 September 2026

Abstract Backgrounds: Fruquintinib is a selective vascular endothelial growth factor receptor (VEGFR)-1/2/3 inhibitor approved for previously treated metastatic colorectal cancer. As its use expands across gastrointestinal (GI) malignancies and combination regimens, randomized evidence is needed to define the toxicity profile most relevant to clinical monitoring, particularly hypertension, dermatologic toxicity, renal toxicity, bleeding, and thrombotic events. The objective of this study was to synthesize randomized controlled trial evidence to quantify the incidence and relative risk of key toxicities associated with fruquintinib in gastrointestinal malignancies. Methods: MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception through 1 January 2026… More >

Lev A. Elkonin^1,*, Grigoriy A. Gerashchenkov²

Phyton-International Journal of Experimental Botany, Vol.95, No.8, 2026, DOI:10.32604/phyton.2026.081317 - 28 August 2026

Abstract Sorghum is a heat- and drought-tolerant cereal crop used for feed and food purposes in more than 100 countries. Sorghum becomes highly important in conditions of climate warming. The use of genome editing technologies is of paramount importance for this crop, which has a number of constraints in key agronomic traits that are difficult for improvement using conventional breeding. Application of genome editing for sorghum is limited due to problems of genetic transformation; however, recent advances in this field have increased the efficiency of the genome editing procedure in sorghum. This review summarizes recent achievements More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090481 - 13 August 2026

Abstract This article has no abstract. More >

Shih-Wei Chiang^1,2, Ming-Cheng Chen^2,3, Chang-Lin Lin², Yi-Lin Huang², Feng-Fan Chiang^2,4,*, Shun-Fa Yang^1,5,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085229 - 13 August 2026

Abstract Background: Anti-EGFR therapy is widely used as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with RAS wild-type mCRC. Methods: We retrospectively analyzed 241 patients with RAS wild-type mCRC treated with first-line chemotherapy plus panitumumab (n = 76), cetuximab (n = 80), or bevacizumab (n = 85) between 2016 and 2024. Outcomes included depth of response… More >

Chenchen Wang^1,2, Mingzhu Huang^1,2, Wenhua Li^1,2, Xuedan Sheng^1,2, Xiaoying Zhao^1,2, Xiaodong Zhu^1,2, Zhiyu Chen^1,2, Zhe Zhang^1,2, Haiming Li^2,3, Weijian Guo^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084378 - 13 August 2026

Abstract Background: Patients with refractory metastatic colorectal cancer (mCRC) face limited treatment options after failure of standard therapies. This single-arm, phase II study aimed to evaluate the efficacy and safety of rechallenge strategies using previously effective regimens in late-line mCRC. Methods: Patients who progressed after ≥2 lines of prior chemotherapy, with a prior progression-free survival (PFS) ≥4 months and a ≥4-month treatment-free interval on that regimen were enrolled. Patients received rechallenge chemotherapy (oxaliplatin-, irinotecan-, or raltitrexed-based) with or without targeted agents (bevacizumab or cetuximab). Primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR), disease… More >

Wen Gao^1,2, Xingyu Zheng^1,2, Yanan Hu^1,2, Rui Zou³, Yongan Zhou⁴, Xiang Song^2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082652 - 13 August 2026

Abstract Background: As a core component of the immunoproteasome, the β1i subunit (proteasome 20S subunit beta 9, PSMB9) is involved in antigen processing and presentation and regulates anti-tumor immune responses. PSMB9 is aberrantly overexpressed in colorectal cancer. However, the precise mechanisms through which PSMB9 contributes to the initiation, progression, and immune regulation of colorectal cancer remain unclear. This study aims to investigate the expression characteristics and biological functions of PSMB9 in colorectal cancer, and to further elucidate the molecular pathways underlying its role in colorectal cancer initiation and progression. The findings are expected to provide a theoretical… More >

Carlo Signorelli^1,*, Michele Basso², Annunziato Anghelone², Maria Alessandra Calegari², Alessandro Passardi³, Chiara Gallio³, Alessandro Bittoni³, Jessica Lucchetti⁴, Lorenzo Angotti⁴, Emanuela Di Giacomo⁴, Ina Valeria Zurlo⁵, Cristina Morelli⁶, Emanuela Dell’Aquila⁷, Adele Artemi⁷, Donatello Gemma⁸, Domenico Cristiano Corsi⁹, Alessandra Emiliani⁹, Marta Ribelli⁹, Federica Mazzuca¹⁰, Giulia Arrivi¹⁰, Federica Zoratto¹¹, Maria Grazia Morandi¹², Fiorenza Santamaria^13,14, Manuela Dettori¹⁵, Antonella Cosimati¹⁶, Rosa Saltarelli¹⁷, Alessandro Minelli¹⁸, Emanuela Lucci-Cordisco¹⁹, Mario Giovanni Chilelli¹

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080964 - 13 August 2026

Abstract Background: Trifluridine/tipiracil (T) is a standard treatment for refractory metastatic colorectal cancer (mCRC). In randomized trials, treatment-emergent neutropenia has been associated with improved outcomes, suggesting a potential link with drug activity. However, evidence from routine clinical practice remains limited. This sub-analysis of the multicenter ReTrITA study evaluated the association between severe neutropenia and clinical outcomes in a real-world setting. Methods: Patients with refractory mCRC treated with T within the ReTrITA cohort were included. Patients were stratified according to the occurrence of grade 3–4 neutropenia. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier… More >